Latest News and Press Releases
Want to stay updated on the latest news?
-
Vevey, 3. September 2007 - Mit der erfolgreichen Beendigung des behördlichen Prüfungsverfahrens hat Nestlé die Übernahme von Gerber, Kultmarke für Säuglingsnahrung in den USA, am 31. August 2007 mit...
-
Vevey, 3 September 2007 - As a result of the successful conclusion of the regulatory process, Nestlé completed its acquisition of Gerber, the iconic US baby food brand, on 31 August 2007 with effect...
-
DIRECTORATE CHANGE New York and Stockholm - September 3, 2007 - Millicom International Cellular S.A. (Nasdaq Stock Market: MICC and Stockholmsbörsen: MIC), the global telecommunications company,...
-
Basel, September 3, 2007 - Novartis has completed the sale of its Gerber baby foods business to Nestlé for USD 5.5 billion, the final step in a divestment program to focus the Group's strategy on...
-
Reported via Company News Service on 3 September 2007: ANNOUNCEMENT OF THE RESULT OF STODIR'S VOLUNTARY CONDITIONAL TENDER OFFER TO ALL SHAREHOLDERS IN KEOPS A/S Not to be published or...
-
Vevey, 3 September 2007 - As a result of the successful conclusion of the regulatory process, Nestlé completed its acquisition of Gerber, the iconic US baby food brand, on 31 August 2007 with effect...
-
Die Lysser Feintool-Gruppe, führende Technologie- und Systemanbieterin sowie globale Komponentenzulieferin, hat den bisher interimistisch tätigen Werner Lang definitiv als Divisionsleiter...
-
The Feintool Group, a leading technology and systems provider and a global components supplier based in Lyss (Switzerland), has now confirmed Werner Lang as the permanent head of its Plastic/Metal...
-
Le groupe lyssois Feintool, premier fournisseur de technologies et de systèmes et sous-traitant global de composants, a confirmé que Werner Lang, qui travaillait jusqu'ici à titre intérimaire,...
-
VIENNA, Austria, Sept. 3, 2007 (PRIME NEWSWIRE) -- At the 2007 European Society of Cardiology (ESC) congress in Vienna, Actelion Ltd (SWX:ATLN) has presented full results from a Phase IIIb trial(1)...